Dr. Aditya Bardia on RAD1901 in ER-Positive Metastatic Breast Cancer
January 29th 2016
Aditya Bardia, MD, MPH, assistant professor of Medicine, Harvard Medical School, attending physician, Medical Oncology, Massachusetts General Hospital, discusses RAD1901, a selective estrogen receptor degrader (SERD) for potential use in ER-positive metastatic breast cancer.